USPTO trademark

AIRNEXIS THERAPEUTICS

Under examinationUSPTOWord and designClass 5Class 42Class 44

"AIRNEXIS THERAPEUTICS" is a word and design mark owned by AirNexis Therapeutics, Inc., filed at the USPTO on October 27, 2026. It is under examination and covers classes 5, 42 and 44.

Get this data via the API
Official USPTO record
AIRNEXIS THERAPEUTICS trademark as filed
As filed with the USPTO
Status
Under examination
Since October 27, 2026
Filed
October 27, 2026
Registered
Not yet
Expires
Not recorded
Application no.
50185473
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word and design
3 classes
Ownership

Who owns AIRNEXIS THERAPEUTICS

The owner and representative on file with the office.

Owner

AirNexis Therapeutics, Inc.

Redwood City, United States

Representative

Connie L. Ellerbach

Fenwick & West LLP

Goods and services

What the mark covers

The products and services AIRNEXIS THERAPEUTICS is filed for, grouped by Nice class.

  • Pharmaceutical preparations and drugs for the treatment, control, prevention, maintenance, and management of inflammatory and respiratory diseases and symptoms in humans; anti-inflammatory and immunomodulatory pharmaceutical compositions; medications for respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, pneumonia, allergic rhinitis, Idiopathic Pulmonary Fibrosis (IPF), bronchiectasis, chronic cough and other pulmonary disorders; pharmaceutical compositions in the form of tablets, capsules, liquids, aerosols, inhalers, creams, ointments, gels, and injectables for the treatment of inflammatory and respiratory diseases and symptoms in humans; fixed-dose combination pharmaceutical preparations for inflammatory and respiratory diseases and symptoms in humans; combination pharmaceutical preparations comprising two or more active ingredients for inflammatory and respiratory diseases and symptoms in humans; pharmaceutical preparations for use in combination therapy for inflammatory and respiratory diseases and symptoms in humans

  • Research, development, and formulation being research and development of pharmaceuticals for inflammatory and respiratory diseases; pharmaceutical formulation in the nature of pharmaceutical research and development services in the field of inflammatory and respiratory diseases

  • Formulation of pharmaceuticals, namely, pharmaceutical compounding for inflammatory and respiratory diseases; pharmaceutical formulation, namely, pharmaceutical compounding services in the field of inflammatory and respiratory diseases

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Application filing receipt mailed
  2. New application entered
FAQ

About AIRNEXIS THERAPEUTICS

Who owns the trademark "AIRNEXIS THERAPEUTICS"?

The USPTO trademark "AIRNEXIS THERAPEUTICS" (application 50185473) is owned by AirNexis Therapeutics, Inc.

What is the status of "AIRNEXIS THERAPEUTICS"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull AIRNEXIS THERAPEUTICS and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_01a1829f-5a75-74ba-b5eb-0419f5e2eeb7
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_01a1829f-5a75-74ba-b5eb-0419f5e2eeb7",
  "object": "trademark",
  "mark_text": "AIRNEXIS THERAPEUTICS",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "50185473",
  "filing_date": "2026-10-27",
  "nice_classes": [
    5,
    42,
    44
  ],
  "owners": [
    {
      "name": "AirNexis Therapeutics, Inc.",
      "entity_id": null
    }
  ]
}